Polypeptides comprising immunoglobulin single variable domains targeting tnfa and il-23
AssigneesAblynx N.V., Sanofi
InventorsHeidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
Life of this patent
Estimating the term…
Abstract
The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNFα and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
Claims19
A polypeptide that specifically binds TNFα and the p19 subunit of IL-23, wherein the polypeptide comprises at least three immunoglobulin single variable domains (ISVDs), wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), optionally linked via one or more peptidic linkers;
- and wherein:
- a) a first ISVD comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO:
- 6;
- ii. a CDR2 that is the amino acid sequence of SEQ ID NO:
- 10;
- and
- iii. a CDR3 that is the amino acid sequence of SEQ ID NO:
- 14;
- b) a second ISVD comprises
- iv. a CDR1 that is the amino acid sequence of SEQ ID NO:
- 7;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO:
- 11;
- and
- vi. a CDR3 that is the amino acid sequence of SEQ ID NO:
- 15;
- and
- c) a third ISVD comprises
- vii. a CDR1 that is the amino acid sequence of SEQ ID NO:
- 9;
- viii. a CDR2 that is the amino acid sequence of SEQ ID NO:
- 13;
- and
- ix. a CDR3 that is the amino acid sequence of SEQ ID NO:
- 17.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1.
A polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.